• September 23, 2019

Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development - Odessa American: Business

e-Edition Subscribe

Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development

Print
Font Size:
Default font size
Larger font size

Posted: Tuesday, September 10, 2019 6:00 am | Updated: 6:31 am, Tue Sep 10, 2019.

MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development. Mr. Hasija brings to Milestone two decades of experience in corporate finance and business development within the healthcare industry.

"It is a pleasure to welcome Amit to the Milestone team," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "His extensive experience across a range of financial and business development roles will be invaluable as we continue to advance our Phase 3 program of etripamil for PSVT, prepare our commercialization strategy, and begin to build out our pipeline. I look forward to working with Amit as we strive towards our goal of bringing effective therapies to patients with episodic cardiovascular conditions."

"I am excited to be joining such a highly accomplished team at this important juncture for the Company," said Mr. Hasija. "I look forward to contributing to Milestone's continued success as the etripamil development program progresses."

Mr. Hasija most recently served as Chief Financial Officer and Chief Business Officer at Fulcrum Therapeutics, a publicly traded, clinical-stage biopharmaceutical company focused on developing therapies for genetically defined rare diseases. Prior to Fulcrum, he spent five years at Sanofi, most recently serving as Vice President of Integrated Care, where he was responsible for developing cardiovascular and diabetes value-based contracting models. While at Sanofi, he also served as Vice President of North America Pharmaceutical Business Development, and was responsible for identifying external opportunities and executing in-licensing, co-promotion, partnership, and acquisition activities in multiple therapeutic areas, including cardiovascular, immunology, diabetes, oncology, renal, and biosurgery. Prior to joining Sanofi, Mr. Hasija spent more than a decade at Goldman Sachs, Credit Suisse and Deutsche Bank, where he executed mergers and acquisitions and corporate finance transactions for healthcare clients. He began his career at Merck as a Planning and Logistics Analyst and Operations Manager. Mr. Hasija earned a B.S. in Chemical Engineering from Drexel University and received an MBA from New York University's Stern School of Business.

About Milestone Pharmaceuticals

Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT) as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

Contact

David Pitts Argot Partners 212-600-1902 david@argotpartners.com

View original content to download multimedia: http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-announces-appointment-of-amit-hasija-as-chief-financial-officer-and-executive-vice-president-of-corporate-development-300914329.html

SOURCE Milestone Pharmaceuticals, Inc.

© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Fair
70°
Humidity: 91%
Winds: E at 6mph
Feels Like: 70°

Your Extended Forecast

Tomorrow

weather
High 89°/Low 70°
Afternoon thunderstorms. Highs in the upper 80s and lows in the low 70s.

tuesday

weather
High 90°/Low 70°
Partly cloudy. Highs in the low 90s and lows in the low 70s.

wednesday

weather
High 92°/Low 70°
Partly cloudy. Highs in the low 90s and lows in the low 70s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7670 to sign up today.